New study follows COPD patients on triple inhaler to measure Real-World benefits
NCT ID NCT06511193
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 32 times
Summary
This study follows 152 adults with COPD who start taking a three-in-one inhaler (budesonide/glycopyrronium/formoterol, or BGF) as part of their routine care. Researchers want to see how the treatment affects symptoms, quality of life, and the number of flare-ups over six months. Participants are already receiving the inhaler from their doctor, and the study simply tracks their progress using questionnaires and medical records.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Windsor, Ontario, N8W 5V7, Canada
Conditions
Explore the condition pages connected to this study.